MedTrace Logo

Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

NCT00313079 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2012-07-03

No results posted yet for this study

Summary

A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety, pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with vincristine.

Conditions

  • Leukemia, Lymphocytic
  • Leukemia
  • Acute Lymphocytic Leukemia

Interventions

DRUG

MAb 216

Dosage: 1.25mg/kg intravenous with dose escalation

DRUG

Vincristine

Dosage: 1.5mg/m2 intravenous weekly X 4

Sponsors & Collaborators

  • Steven E. Coutre

    lead OTHER

Principal Investigators

  • Nelson N Teng · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-02-28
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00313079 on ClinicalTrials.gov